Search for: [Abstract = "Physician's and Dentist's Profession Act \(PDPA\) imposes an obligation on Polish physicians to prescribe only drugs licensed for trade in the Republic of Poland. The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products authorizes the introduction of drugs to Polish market based upon the Summary of Product Characteristic \(SPC\) that \- among others \- defines the official indications for the use of a drug. According to the Polish Act on Pharmaceutical Law and the PDPA, prescribing a drug for treating diseases that are not among official indications listed in the SPC \('off\-label' use\) could be interpreted as a ‘medical experiment’, leading to a range of legal and financial consequences for the doctor. Moreover, the ‘off\-label’ prescription results as a rule in the denial of drug reimbursement. The aim of this study was to analyze the concordance between official indications as determined in the SPC of drugs registered in Poland for treating diseases from the spectrum of eczema with up\-to\-date expert guidelines and the scientific evidence for the efficacy of recommended and registered of recommended and registered drugs. The policy of drug reimbursement was also analysed with this regard."]

Number of results: 2